Table 2 Quantitative statistically significant results (achieved 3 of 4 demarcated critical cut-off criteria of controls compared to TBM stages 1, 2 and 3).

From: The diagnostic potential of urine in paediatric patients undergoing initial treatment for tuberculous meningitis

Annotations	Bins	Stage 1 TBM				Stage 2 TBM				Stage 3 TBM
Annotations	Bins	VIP	FDR	FC	ES	VIP	FDR	FC	ES	VIP	FDR	FC	ES
Rifampicin/3-formylrifampicin	0.59	2.21	< 0.01	7.65	2.27
Rifampicin/3-formylrifampicin	0.61	2.04	< 0.01				< 0.01	8.02	2.84		< 0.01	5.50	2.06
Propylene glycol	1.13				2.26	1.56	< 0.01	35.30	3.00		< 0.01	22.53	2.11
Propylene glycol	1.15				2.84
X1	1.55				2.70	1.52	< 0.01		3.32
X2	1.57				4.13	1.61	< 0.01		4.79	1.52	< 0.01		3.59
N-Acetylglutamine	2.07	1.50	< 0.01			1.54	< 0.01		4.38		< 0.01	5.87	2.66
Acetylisoniazid	2.15	1.88	< 0.01		3.49	1.61	< 0.01		3.79
Succinic acid	2.41	1.56	< 0.01		3.11	1.50	< 0.01	8.16	3.50
5-Aminolevulinic acid	2.53	1.87	< 0.01		2.94
Citric acid	2.67	1.51	< 0.01								< 0.01	8.01	1.62
5-Aminolevulinic acid	2.81				3.85	1.58	< 0.01		3.53	1.58	< 0.01		3.73
X3	3.17	1.73	< 0.01		3.39	1.60	< 0.01		4.26
X4	3.39						< 0.01	7.46	1.22
Propylene glycol	3.45				1.01
Propylene glycol	3.47				2.53	1.56	< 0.01	5.52	2.31
Propylene glycol	3.55	1.62	< 0.01			1.56	< 0.01		3.14	1.52	< 0.01		3.14
Propylene glycol	3.89	1.65	< 0.01				< 0.01	5.32	2.15		< 0.01	5.11	1.80
N-Acetylglutamine	4.15	1.58	< 0.01		2.16	1.63	< 0.01	8.21	2.31	1.52	< 0.01	7.59	2.35
X5	4.29				2.04	1.60	< 0.01	14.04	2.77	1.54	< 0.01	11.79	2.02
X6	4.41	1.52	< 0.01				< 0.01	5.78	1.60
X7	4.61	1.56	< 0.01		1.96		< 0.01	5.43	1.22		< 0.01	5.87	1.30
X8	5.17				1.41		< 0.01	5.55	1.77
X9	5.19	1.86	< 0.01				< 0.01	7.55	1.16		< 0.01	8.66	1.26
Rifampicin/3-formylrifampicin	6.33	1.62	< 0.01		3.15		< 0.01	10.10	2.08		< 0.01	9.96	2.02
Rifampicin/3-formylrifampicin	6.35	1.95	< 0.01				< 0.01	5.81	3.08		< 0.01	6.66	2.00
X10	6.81				4.40	1.57	< 0.01	23.83	4.51		< 0.01	19.22	2.81
X11	7.21				3.68		< 0.01	8.15	2.52		< 0.01	6.31	2.18
Isoniazid	7.71	1.89	< 0.01		2.19	1.50	< 0.01	28.72	1.64		< 0.01	22.71	1.22
X12	7.73	1.80	< 0.01		3.36		< 0.01	43.01	3.12		< 0.01	31.00	2.34
Isonicotinic acid	7.75	2.24	< 0.01	8.39			< 0.01	6.19	1.26		< 0.01	5.89	1.64
Isonicotinic acid	7.77	1.86	< 0.01		2.75
2-Pyridin-4-formidoacetic acid	7.79	2.27	< 0.01	12.13	1.48						< 0.01	5.67	1.31
Acetylisoniazid	7.81	2.18	< 0.01	12.57	1.27		< 0.01	10.95	2.33		< 0.01	6.94	1.29
Quinolinic acid	8.05						< 0.01	12.68	1.10
X13	8.59	1.78	< 0.01		1.55		< 0.01	7.40	2.21		< 0.01	7.94	1.92
Isonicotinic acid	8.61	2.34	< 0.01	21.60			< 0.01	16.45	1.00		< 0.01	8.17	1.05
Isonicotinic acid	8.63	2.38	< 0.01	44.73		1.56	< 0.01	9.51	1.22
X14	8.65	2.02	< 0.01		1.20	1.68	< 0.01	16.13	1.65	1.62	< 0.01	16.73	1.25

The annotations given to the bins were based upon 1D and 2D ¹H-NMR spectral library matches. VIP variables important in projection (OPLSDA). FDR Wilcoxon p value adjusted for multiple tests. FC fold change. ES Hedge’s g value effect size. X indicates an unknown compound.

Back to article page

Table 2 Quantitative statistically significant results (achieved 3 of 4 demarcated critical cut-off criteria of controls compared to TBM stages 1, 2 and 3).

Search

Quick links